{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:20:18Z","timestamp":1778592018258,"version":"3.51.4"},"reference-count":41,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Providence Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: The selection of neoadjuvant therapy for patients with non-metastatic pancreatic adenocarcinoma remains challenging. Methods: We performed a single-institution, retrospective analysis of 79 patients who underwent resection of their pancreatic adenocarcinoma after receiving neoadjuvant therapy. Clinical and pathologic data were collected. Tumor fibrosis was quantified using Masson\u2019s trichrome staining, tumor-infiltrating lymphocytes (TIL) were evaluated by an AI-based analysis of whole-slide H&amp;E images, and immune cell populations were quantified by multiplex immunohistochemistry. Correlation analyses were performed between neoadjuvant treatment regimen, tumor regression, immune phenotypes, and survival. Results: All patients received chemotherapy, 77% FOLFIRINOX and 23% Gemcitabine\/nab-paclitaxel (Abraxane). Eighteen percent of patients went on to receive radiation. Tumor regression grade (TRG) correlated with the neoadjuvant regimen. A reduction in tumor markers and the baseline neutrophil-to-lymphocyte ratio (NLR) correlated with overall survival. Among patients with an NLR &gt; 3.3, FOLFIRINOX conferred a survival benefit over Gemcitabine\/nab-paclitaxel, and radiation trended towards improved survival. Radiation was associated with increased fibrosis and reduced infiltration of CD8+ and regulatory T cells (Tregs). Increased Tregs and PDL1+ stromal cells were associated with poor response to neoadjuvant therapy, and NLR &gt; 3.3 correlated with increased Treg infiltration. Conclusions: Our data suggest that patients with a high baseline NLR may benefit from intensified neoadjuvant therapy with FOLFIRINOX and radiation. Combination immunotherapy targeting Tregs and the PD1\/PDL1 axis may further improve outcomes.<\/jats:p>","DOI":"10.3390\/cancers18101567","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:33:37Z","timestamp":1778589217000},"page":"1567","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Differential Impact of Neoadjuvant Therapies on the Tumor Microenvironment, Peripheral Biomarkers, and Survival in Pancreatic Cancer: A Retrospective Cohort Study"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6214-4806","authenticated-orcid":false,"given":"Trevor","family":"Silva","sequence":"first","affiliation":[{"name":"Providence Cancer Institute, Portland, OR 97213, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Providence Cancer Institute, Portland, OR 97213, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M.","family":"Creasy","sequence":"additional","affiliation":[{"name":"Providence Cancer Institute, Portland, OR 97213, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon M.","family":"Gerry","sequence":"additional","affiliation":[{"name":"Providence Cancer Institute, Portland, OR 97213, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binbin","family":"Zheng-Lin","sequence":"additional","affiliation":[{"name":"Providence Cancer Institute, Portland, OR 97213, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amar J.","family":"Srivastava","sequence":"additional","affiliation":[{"name":"The Oregon Clinic, Portland, OR 97213, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3363-0063","authenticated-orcid":false,"given":"Kristina H.","family":"Young","sequence":"additional","affiliation":[{"name":"Providence Cancer Institute, Portland, OR 97213, USA"},{"name":"The Oregon Clinic, Portland, OR 97213, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"ref_1","first-page":"10","article-title":"Cancer Statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Esmail, A., Dhillon, V., Al-Najjar, E., Khasawneh, B., Alghamdi, M., Ibnshamsah, F., and Abdelrahim, M. (2025). Impact of Tumor Location on Survival Outcomes in Pancreatic Head Versus Body\/Tail Cancer: Institutional Experience. Cancers, 17.","DOI":"10.3390\/cancers17111777"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1245\/s10434-020-09446-x","article-title":"Neoadjuvant Chemotherapy for Pancreatic Adenocarcinoma Lessens the Deleterious Effect of Omission of Adjuvant Chemotherapy","volume":"28","author":"Adam","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"116535","DOI":"10.1016\/j.amjsurg.2025.116535","article-title":"Postoperative Pancreatic Fistula after Pancreaticoduodenectomy: A Contemporary Analysis of a Large National Database","volume":"248","author":"Maegawa","year":"2025","journal-title":"Am. J. Surg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/jnci\/djac018","article-title":"FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium","volume":"114","author":"Janssen","year":"2022","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(16)00172-8","article-title":"FOLFIRINOX for Locally Advanced Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis","volume":"17","author":"Suker","year":"2016","journal-title":"Lancet. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"v253","DOI":"10.1093\/annonc\/mdz247","article-title":"Conversion Rate in Locally Advanced Pancreatic Cancer (LAPC) after Nab-Paclitaxel\/Gemcitabine- or FOLFIRINOX-Based Induction Chemotherapy (NEOLAP): Final Results of a Multicenter Randomised Phase II AIO Trial","volume":"30","author":"Kunzmann","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jamaoncol.2020.7328","article-title":"Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma","volume":"7","author":"Sohal","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1001\/jamasurg.2020.2286","article-title":"Response and Survival Associated With First-Line FOLFIRINOX vs Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma","volume":"155","author":"Perri","year":"2020","journal-title":"JAMA Surg."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41586-022-05272-1","article-title":"LRRC15+ Myofibroblasts Dictate the Stromal Setpoint to Suppress Tumour Immunity","volume":"611","author":"Krishnamurty","year":"2022","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.ccell.2026.03.004","article-title":"Myofibroblast Programming Blocks Differentiation of TLS-Organizing Fibroblastic Reticular Cells in Pancreatic Cancer","volume":"44","author":"Kirschstein","year":"2026","journal-title":"Cancer Cell"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/jnci\/djaa073","article-title":"Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy","volume":"113","author":"Michelakos","year":"2021","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2066767","DOI":"10.1080\/2162402X.2022.2066767","article-title":"Neoadjuvant Chemoradiation Alters the Immune Microenvironment in Pancreatic Ductal Adenocarcinoma","volume":"11","author":"Gartrell","year":"2022","journal-title":"Oncoimmunology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/cas.70320","article-title":"Neoadjuvant Therapy-Induced Remodeling in Pancreatic Ductal Adenocarcinoma: Multimodal Spatial Analysis and Prognosis","volume":"117","author":"Zhang","year":"2026","journal-title":"Cancer Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1158\/1078-0432.CCR-19-1864","article-title":"Neoadjuvant Therapy Remodels the Pancreatic Cancer Microenvironment via Depletion of Protumorigenic Immune Cells","volume":"26","author":"Teller","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41698-025-00848-2","article-title":"Complement Activation in Tumor Microenvironment after Neoadjuvant Therapy and Its Impact on Pancreatic Cancer Outcomes","volume":"9","author":"Zhang","year":"2025","journal-title":"npj Precis. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","article-title":"Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma","volume":"33","author":"Royal","year":"2010","journal-title":"J. Immunother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s40425-018-0367-1","article-title":"Pan-Cancer Adaptive Immune Resistance as Defined by the Tumor Inflammation Signature (TIS): Results from The Cancer Genome Atlas (TCGA)","volume":"6","author":"Danaher","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The Immune Landscape of Cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Bernard, B., Rajamanickam, V., Dubay, C., Piening, B., Alonso, E., Jutric, Z., Tang, E., Newell, P., Hansen, P., and Medler, T. (2020). Transcriptional and Immunohistological Assessment of Immune Infiltration in Pancreatic Cancer. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0238380"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1900635","DOI":"10.1080\/2162402X.2021.1900635","article-title":"Germinal Center Reactions in Tertiary Lymphoid Structures Associate with Neoantigen Burden, Humoral Immunity and Long-Term Survivorship in Pancreatic Cancer","volume":"10","author":"Gunderson","year":"2021","journal-title":"Oncoimmunology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41698-024-00681-z","article-title":"Barriers and Opportunities in Pancreatic Cancer Immunotherapy","volume":"8","author":"Ju","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"8297","DOI":"10.1245\/s10434-021-10276-8","article-title":"Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis","volume":"28","author":"Janssen","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"783","DOI":"10.6004\/jnccn.2022.7008","article-title":"Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study","volume":"20","author":"Janssen","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: Open Source Software for Digital Pathology Image Analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41698-024-00499-9","article-title":"Open and Reusable Deep Learning for Pathology with WSInfer and QuPath","volume":"8","author":"Kaczmarzyk","year":"2024","journal-title":"Precis. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.3748\/wjg.v21.i9.2807","article-title":"Prognostic Significance of Neutrophil to Lymphocyte Ratio in Pancreatic Cancer: A Meta-Analysis","volume":"21","author":"Yang","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.semradonc.2019.12.004","article-title":"Effects of Radiation on the Tumor Microenvironment","volume":"30","author":"Monjazeb","year":"2020","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib","volume":"315","author":"Hammel","year":"2016","journal-title":"JAMA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1200\/JCO.19.02274","article-title":"Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial","volume":"38","author":"Versteijne","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1200\/JCO.21.02233","article-title":"Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial","volume":"40","author":"Versteijne","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jamaoncol.2022.2319","article-title":"Efficacy of Preoperative MFOLFIRINOX vs MFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas","volume":"8","author":"Katz","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"110064","DOI":"10.1016\/j.radonc.2023.110064","article-title":"Stereotactic MR-Guided on-Table Adaptive Radiation Therapy (SMART) for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-Center, Open-Label Phase 2 Study","volume":"191","author":"Chuong","year":"2024","journal-title":"Radiother. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s11605-017-3660-2","article-title":"Association Between the Incidence of Pancreatic Fistula After Pancreaticoduodenectomy and the Degree of Pancreatic Fibrosis","volume":"22","author":"Deng","year":"2018","journal-title":"J. Gastrointest. Surg."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.sopen.2025.12.004","article-title":"Inflammation and Fibrosis at Pancreatic Resection Margin and Their Role in Post-Operative Pancreatic Fistula Development After Pancreaticoduodenectomy: A Pilot Study From a Single Institution","volume":"29","author":"Cammarata","year":"2026","journal-title":"Surg. Open Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1001\/jamasurg.2018.1757","article-title":"Association of Immunologic Markers With Survival in Upfront Resectable Pancreatic Cancer","volume":"153","author":"Tang","year":"2018","journal-title":"JAMA Surg."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1001\/jamaoncol.2019.1588","article-title":"Durvalumab with or Without Tremelimumab for Patients with Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial","volume":"5","author":"Oh","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1038\/s41467-022-32591-8","article-title":"The CCTG PA.7 Phase II Trial of Gemcitabine and Nab-Paclitaxel with or without Durvalumab and Tremelimumab as Initial Therapy in Metastatic Pancreatic Ductal Adenocarcinoma","volume":"13","author":"Renouf","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e155006","DOI":"10.1172\/jci.insight.155006","article-title":"Dual IL-6 and CTLA-4 Blockade Regresses Pancreatic Tumors in a T Cell\u2013 and CXCR3-Dependent Manner","volume":"8","author":"Ware","year":"2023","journal-title":"JCI Insight"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1158\/2326-6066.CIR-14-0215","article-title":"Induction of T-Cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma","volume":"3","author":"Winograd","year":"2015","journal-title":"Cancer Immunol. Res."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/10\/1567\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:02:31Z","timestamp":1778590951000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/10\/1567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":41,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["cancers18101567"],"URL":"https:\/\/doi.org\/10.3390\/cancers18101567","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]}}}